VEXAS: is it time to reshape the nosology of clonal hematopoiesis?

The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes. Clonal expansion driven by somatic mutations in cancer genes has been largely described in healthy aging individuals. Regarding hematopoiesis, the prevalence of clonal hematopoiesis has blurred the line between normal and pathological, especially for the definition of myelodysplastic syndromes. VEXAS syndrome further challenges the nosology as this clonal disease of hematopoiesis is also associated with dysplastic features and cytopenias. In this perspective, we discuss whether VEXAS should be considered a genuine myelodysplastic syndrome and propose a conceptual framework to refine the nosology, based on the distinction of clonal hematopoiesis of indeterminate potential (CHIP), clonal hematopoiesis of hematological significance, and clonal hematopoiesis of other significance.

Citation

Pierre Sujobert, Laetitia Largeaud, Yvan Jamilloux, Maël Heiblig, Olivier Kosmider. VEXAS: is it time to reshape the nosology of clonal hematopoiesis? Expert review of hematology. 2023 Jul-Dec;16(7):495-499

Mesh Tags

PMID: 37119011

search → result